Smith & Nephew Snats ( (SNN) ) just unveiled an update.
Smith & Nephew reported its fourth quarter and full year 2024 financial results, highlighting a transformative 12-Point Plan that has driven higher revenue growth, margin expansion, and strong cash flow. The company saw a 4.7% increase in full-year revenue to $5,810 million and a 54.6% rise in operating profit to $657 million. Despite challenges such as inflation and headwinds from China, the company’s organizational changes and product innovations have contributed to improved financial performance. The company expects further performance improvements in 2025, including significant margin expansion.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company that specializes in products for orthopedics, sports medicine, and advanced wound management. The company focuses on innovation and has launched nearly 50 new products over the last three years, with a strong pipeline planned for 2025.
YTD Price Performance: 7.70%
Average Trading Volume: 750,917
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.49B
See more data about SNN stock on TipRanks’ Stock Analysis page.